Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab as bridging therapy in corticodependent Crohn's disease
NCT00796250Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2003
- Primary completion
- Jan 2005
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of infliximab in Crohn's disease, sponsored by Merck & Co.. Started Nov 2003; status: terminated.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00796250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796250.